Your browser doesn't support javascript.
loading
Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study.
Bricheux, A; Lenggenhager, L; Hughes, S; Karmime, A; Lescuyer, P; Huttner, A.
Affiliation
  • Bricheux A; Geneva University Faculty of Medicine, Geneva, Switzerland.
  • Lenggenhager L; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
  • Hughes S; Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland.
  • Karmime A; Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland.
  • Lescuyer P; Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Geneva, Switzerland.
  • Huttner A; Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. Electronic address: angela.huttner@hcuge.ch.
Clin Microbiol Infect ; 25(3): 383.e1-383.e4, 2019 Mar.
Article de En | MEDLINE | ID: mdl-30528370
ABSTRACT

OBJECTIVES:

Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is increasingly employed to ensure adequate antibiotic exposure and slow emergence of resistance. Imipenem's therapeutic range has not been defined; we report plasma concentrations and clinical outcomes of patients receiving imipenem for bacterial infections.

METHODS:

All hospitalized adult patients undergoing imipenem TDM during therapy for suspected or confirmed bacterial infections between 1 January 2013 and 28 February 2017 were included in this single-centre retrospective cohort. The primary outcome was incidence of clinical toxicity; secondary outcomes included incidence of clinical failure and median imipenem concentrations in those with and without toxicity and/or failure. Total imipenem concentrations were measured via high-performance liquid chromatography with ultraviolet detection.

RESULTS:

A total of 403 imipenem levels were drawn from 300 patients. Fifteen (5%) patients experienced an adverse event considered at least possibly related to imipenem. Eighty-eight (29%) patients had clinical failure; augmented renal clearance appeared to emerge as a protective factor against failure (OR 0.42; 95% CI 0.20-0.89). Median first-measure trough concentration was 3.2 mg/L (IQR 1.7-6.5). Patients with suspected toxicity did not have higher concentrations. Patients whose dose was not increased after a trough level <2 mg/L was returned trended towards increased clinical failure (3/28 (11%) vs. 12/63 (19%)), though the difference was not statistically significant.

CONCLUSIONS:

Toxicity was rare and clinical failure frequent in this cohort of patients whose imipenem concentrations were generally low and occasionally undetectable. Larger trials are needed to define optimal imipenem exposure.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Infections bactériennes / Imipénem / Antibactériens Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Clin Microbiol Infect Sujet du journal: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Infections bactériennes / Imipénem / Antibactériens Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Clin Microbiol Infect Sujet du journal: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Suisse
...